Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Parkinson's Disease

Free Subscription 25.08.2025 1 Brain Res 2 Exp Neurol 1 J Clin Psychopharmacol 2 J Neural Transm (Vienna) 5 Mov Disord 2 Nat Med 1 Neurobiol Dis 1 Neurology 1 Neuropsychology 3 Neuroscience 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Brain Res

1. KENTROS M, Follett J, Subrahmanian N, Chairmandurai A, et al
   Regulation of LRRK2 activity by metabolic stress and heavy metal exposure.
   Brain Res. 2025;1863:149785.
   PubMed         Abstract available
   
   

   
   Exp Neurol

2. WU X, Hui Y, Wang L, Qiao H, et al
   Long-term intermittent theta burst stimulation alleviates Parkinson's disease-related cognitive impairment by modulating GluN2B in the dorsal hippocampus.
   Exp Neurol. 2025;394:115439.
   PubMed         Abstract available
   
   
3. MIN X, Du Z, Wei J, Yuan Z, et al
   Corrigendum to "Pyridoxal Phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's Disease" [Experimental Neurology (2025) 115411].
   Exp Neurol. 2025 Aug 20:115429. doi: 10.1016/j.expneurol.2025.115429.
   PubMed        
   
   

   
   J Clin Psychopharmacol

4. PIRES AC, Faria I, Bajouco M, Mota D, et al
   Clozapine-Resistant Schizophrenia and Wolff-Parkinson-White Syndrome: A Case Report.
   J Clin Psychopharmacol. 2025 Aug 22. doi: 10.1097/JCP.0000000000002055.
   PubMed        
   
   

   
   J Neural Transm (Vienna)

5. MULLER T, Ohm G, Eilert K, Haas T, et al
   Olfaction function improves in a specialised unit for Parkinson's disease.
   J Neural Transm (Vienna). 2025 Aug 21. doi: 10.1007/s00702-025-02987.
   PubMed         Abstract available
   
   
6. RUKAVINA K, Mulholland N, Corcoran B, Skoric MK, et al
   Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.
   J Neural Transm (Vienna). 2025 Aug 16. doi: 10.1007/s00702-025-02999.
   PubMed         Abstract available
   
   

   
   Mov Disord

7. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
   Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
   Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
   PubMed         Abstract available
   
   
8. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
   Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
   Mov Disord. 2025;40:1604-1617.
   PubMed         Abstract available
   
   
9. YIN KF, Gu XJ, Yu JM, Su WM, et al
   Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
   Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
   PubMed         Abstract available
   
   
10. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    PubMed         Abstract available
    
    
11. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    PubMed         Abstract available
    
    

    
    Nat Med

12. IMAM F, Saloner R, Vogel JW, Krish V, et al
    The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
    Nat Med. 2025;31:2556-2566.
    PubMed         Abstract available
    
    
13. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
    APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
    Nat Med. 2025;31:2590-2601.
    PubMed         Abstract available
    
    

    
    Neurobiol Dis

14. GRILLO P, Di Martino D, Calculli A, De Icco R, et al
    Physical exercise modulates plasma irisin levels in endurance athletes: Implications for Parkinson's disease.
    Neurobiol Dis. 2025 Aug 23:107065. doi: 10.1016/j.nbd.2025.107065.
    PubMed         Abstract available
    
    

    
    Neurology

15. ZHANG X, Wang J, Dove A, Yu T, et al
    Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis.
    Neurology. 2025;105:e214033.
    PubMed         Abstract available
    
    

    
    Neuropsychology

16. BARVAS E, Mattavelli G, Guttmann S, Papagno C, et al
    Using the Modified Taylor Complex Figure-Recognition Trial (MTCF-RT) to differentiate amnestic patients with Alzheimer's disease from patients with memory deficits due to Parkinson's disease or subcortical ischemic vascular dementia.
    Neuropsychology. 2025 Aug 25. doi: 10.1037/neu0001036.
    PubMed         Abstract available
    
    

    
    Neuroscience

17. ATANASOVSKI D, Bergquist F, Eriksson E, Carlsson T, et al
    The dopamine stabilizer (-)-OSU6162 attenuates levodopa-induced dyskinesia in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Neuroscience. 2025 Aug 23:S0306-4522(25)00889.
    PubMed         Abstract available
    
    
18. DA SILVA CHAAR NETA R, da Silva Batista C, Machado Palmerim EM, Costa Dias HM, et al
    The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson's Disease: a systematic review.
    Neuroscience. 2025;584:113-126.
    PubMed         Abstract available
    
    
19. GWEDELA MNV, Gadama Y, Phiri TE
    Parkinson's disease in Malawi: A cross-sectional Study of clinical profiles and risk factors.
    Neuroscience. 2025;584:88-92.
    PubMed         Abstract available
    
    

    
    PLoS One

20. UMEMURA A, Sato K, Iwamuro H, Uchiyama S, et al
    Effects of transcranial direct current stimulation using a commercially available device on gait in Parkinson's disease with freezing of gait.
    PLoS One. 2025;20:e0330286.
    PubMed         Abstract available
    
    
21. LARSSON V, Hall S, Blennow K, Hansson O, et al
    Olfactory dysfunction and amyloid-positivity in Parkinson's disease-longitudinal analysis of cognitive decline and cerebrospinal fluid markers.
    PLoS One. 2025;20:e0325560.
    PubMed         Abstract available
    
    
22. PAPIC E, Racki V, Hero M, Zimani AN, et al
    Microbial diversity in drug-naive Parkinson's disease patients.
    PLoS One. 2025;20:e0328761.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.